ADVERTISEMENT
High-Dose Naloxone Product Launches in US
USWM and Adamis Pharmaceuticals Corporation have announced the US launch and availability of a high-dose injectable naloxone product to help combat opioid overdose deaths.
The product, known as ZIMHI, is approved by the Food and Drug Administration (FDA) for use in the treatment of opioid overdose as emergency therapy in settings where opioids may be present. The high-dose formulation is a response to the rise of the powerful synthetic fentanyl, which, along with fentanyl analogs and other synthetic opioids, is now responsible for about 85% of opioid overdose-related deaths.
“Successfully treating overdoses involving fentanyl often requires multiple doses of lower-dose or intranasal naloxone products, creating an urgent need for new tools to help combat these more powerful opioids,” US WorldMeds CEO P. Breckinridge Jones Sr said in a news release.
ZIMHI is being made available at a discounted rate for first responders and community health organizations. Additional information is available at: zimhi.com/public-service.
Reference
